Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADG116 + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADG116 | ADG-116|ADG 116|Firastotug | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | ADG116 is a monoclonal antibody that targets CTLA4, which potentially induces antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). | |
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04501276 | Phase I | ADG116 ADG106 + ADG116 ADG116 + unspecified PD-1 antibody | A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients | Active, not recruiting | USA | AUS | 0 |